On January 6, Yifan Pharmaceutical announced that the company's wholly-owned subsidiary Hefei Yifan Biopharmaceutical Co., Ltd. signed an “Exclusive Commercial Cooperation Agreement” and “Cornerstone Investment Agreement” with Tianjin Suntech Pharmaceutical Technology Co., Ltd. According to the agreement, the company obtained a sublicensable and irrevocable exclusive right and license for ACT001, a next-generation immunomodulator intended to treat small cell lung cancer brain metastasis in East Asian markets such as China and the Southeast Asian market. At the same time, the company can use the licensed intellectual property development, production and commercialization within the aforementioned regions and areas of cooperation, and pay a down payment of 100 million yuan, a 100 million yuan cornerstone investment or 50 million yuan milestone payment, a tiered share of net sales revenue from outside of China; at the same time, the company enjoys other sub-license revenue shares for this product within the cooperative region Exclusive preferential negotiation rights for production and commercialization rights according to indications.

Zhitongcaijing · 4d ago
On January 6, Yifan Pharmaceutical announced that the company's wholly-owned subsidiary Hefei Yifan Biopharmaceutical Co., Ltd. signed an “Exclusive Commercial Cooperation Agreement” and “Cornerstone Investment Agreement” with Tianjin Suntech Pharmaceutical Technology Co., Ltd. According to the agreement, the company obtained a sublicensable and irrevocable exclusive right and license for ACT001, a next-generation immunomodulator intended to treat small cell lung cancer brain metastasis in East Asian markets such as China and the Southeast Asian market. At the same time, the company can use the licensed intellectual property development, production and commercialization within the aforementioned regions and areas of cooperation, and pay a down payment of 100 million yuan, a 100 million yuan cornerstone investment or 50 million yuan milestone payment, a tiered share of net sales revenue from outside of China; at the same time, the company enjoys other sub-license revenue shares for this product within the cooperative region Exclusive preferential negotiation rights for production and commercialization rights according to indications.